Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391333 | 0.87 | ESR1 (0.42) | ESR1ESR2PTGER1MEN1KMT2A | |
| SCHEMBL6010786 | 0.83 | ESR2 (0.40) | ESR2 | |
| SCHEMBL5021458 | 0.77 | NUDT1 (0.41) | — | |
| SCHEMBL6010774 | 0.77 | AHR (0.36) | — | |
| SCHEMBL16391312 | 0.74 | MAOB (0.41) | ESR1ESR2KMT2A | |
| SCHEMBL16391300 | 0.74 | MAOB (0.36) | ESR1ESR2 | |
| SCHEMBL16391287 | 0.73 | GABRA1 (0.40) | ESR1ESR2 | |
| SCHEMBL6010848 | 0.73 | ESR1 (0.39) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL6010802 | 0.72 | LMNA (0.43) | MEN1KMT2A | |
| SCHEMBL9101380 | 0.71 | FBP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-6552057-B2 | In addition to 5-HT3 receptor antagonism, and inhibiting diarrhea without causing constipation as side effect; benzoxazole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0806419-B1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. | 2003-01-16 | — | — | US | disclosed |
| CN-1333771-A | Benzoxazole derivative and drug containing the same as active ingredient | MEIJI SEIKA KAISHA (JP) | 2002-01-30 | — | — | CN | disclosed |
| US-6333328-B1 | MIXING BENZOXAZOLE DERIVATIVE WITH CARRIER TO FORM ACTIVATOR COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6297246-B1 | BENZOXAZOLE DERIVATIVES; DOES NOT CAUSE CONSTIPATION AS A SIDE EFFECT. | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-1134220-A1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6037342-A | BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS | MEIJI SEIKA KAISHA, LTD (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0806419-A1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | HTR7, HTR1A, HTR3A | ESR1 1313/4885ESR2 1813/4885PTGER1 258/4885 |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | HTR7, HTR3A, HTR1A | ESR1 1436/4885ESR2 2069/4885PTGER1 292/4885 |
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | ESR1 3756/4885ESR2 3137/4885PTGER1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.